BioInvent Outlines Strong Progress in Clinical and Preclinical Pipeline at R&D Day 2022

• Current data on BI-1206 show three complete responses (two responses beyond two years) and four partial responses. Full approval received for starting subcutaneous administration.
• Recruitment in single agent and combo arms of BI-1808 Phase 1/2a trial progressing well.
• Dose escalation of BI-1607 progressing well with the first dose cohort completed.
• Results from Part A of BT-001 Phase 1/2a trial to be presented H1 2023E.

LUND, SWEDEN / ACCESSWIRE / December 8, 2022 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, today provides an update on its clinical and pre-clinical pipeline, including an update on its lead drug candidate, the novel anti-FcγRIIB antibody BI-1206.

BI-1206 is currently being studied in two Phase 1/2 trials, in combination with rituximab in non-Hodgkin's lymphoma (NHL) and in combination with pembrolizumab in solid tumors. Latest data from the Phase 1/2 trial with BI-1206 in combination with rituximab in NHL show there are three ongoing complete responses, two beyond two years after end of treatment, and four partial responses, one of which is ongoing. The new arm of the NHL study introducing subcutaneous administration is currently recruiting patients. As anti-CD20 based therapy will remain central for the treatment of NHL, BI-1206 has the potential to be uniquely positioned within NHL.

The ongoing clinical trial with BI-1206 in solid tumors is progressing through the dose-escalation part of the trial and the two patients reported last December still show clear clinical improvement. The subcutaneous arm of the study in solid tumors is on track to be initiated in H1 2023.

"BioInvent is making strong progress with its pipeline of novel immune-modulatory antibodies to treat cancer. We now have five clinical trials in progress with four different drug candidates, underlining the strength of our proprietary technology platform. In particular, the data on our lead drug candidate BI-1206 continue to demonstrate its potential to significantly improve treatment for lymphoma and solid tumor patients. We look forward to continuing to develop BI-1206, and our other promising new treatments, to deliver on the promise of transforming the lives of cancer patients," said Martin Welschof, CEO of BioInvent.